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Herpes simplex virus type 1 (HSV-1)/adenoassociated virus (AAV) hybrid vectors have been designed to overcome the limitations of the parent vector systems, in particular the instability of transgene expression of HSV-1 amplicon vectors and the small transgene capacity of AAV vectors. Indeed, HSV/AAV hybrid vectors have been demonstrated to support site-specific integration in human chromosome 19 and stable transgene expression [1, 2] , even with transgenes as large as 100 kbp [3] . Although other considerable problems exist, including off-target integration and vector-induced immune responses, one of the major hurdles to the use of these hybrid vectors has been the low titers of vector stocks. As HSV-1 is a full helper virus for AAV replication, we are studying the molecular mechanisms of interaction between replicating HSV-1 and AAV in co-infected cells in detail. This may allow us to identify and overcome restrictions in replication efficiency of HSV-1 in the presence of replicative AAV and support the design of novel hybrid vectors that tolerate the presence of multiple origins of DNA replication (oris) from HSV-1 and AAV on the same vector genome. This article focuses on the description of HSV-1 and AAV interactions and the impact of these interactions on HSV/AAV hybrid vector production.
Adeno-associated virus type 2
Adeno-associated virus type 2 (AAV-2) is a widespread, nonpathogenic human parvovirus. The virion has a diameter of approximately 20 nm and consists of an icosahedral capsid, which is composed of a mixture of virion proteins (VPs) 1, 2 and 3. The viral genome is a linear, ssDNA of 4.7 kb containing 145-base inverted terminal repeats (ITRs) at both ends, flanking two clusters of genes, rep and cap, which are controlled by three different promoters, p5, p19 and p40 ( Figure 1A ) [4, 5] . The ITRs can form T-shaped secondary structures; they contain the Repbinding site (RBS) and the terminal resolution site (TRS), which together act as a minimal ori and as a packaging signal [6] [7] [8] [9] . The p5 promoter controlling the synthesis of the large Rep proteins, Rep68 and Rep78, also contains a RBS [10] , which is involved in the Rep-mediated regulation of p5 activity [11, 12] , as well as a functional TRS [13] . Indeed, the TRS and RBS in p5 have been reported to have replication origin activity in the presence of both adenovirus (Ad) and HSV-1 helper functions [14] [15] [16] . The small Rep proteins, Rep40 and Rep52, are translated from spliced and unspliced mRNAs that both originate from the p19 promoter. All three capsid proteins, VP1, VP2 and VP3, are translated from two alternatively spliced mRNA species that originate from a single promoter, p40 [17] . The Kleinschmidt group has recently identified an alternative open reading frame (ORF) of the cap gene, which encodes an AAV-2 protein termed 'assembly activating protein' (AAP). AAP targets newly synthesized capsid proteins to the nucleolus where capsid assembly occurs and, in addition, it fulfils a function in the assembly reaction itself [18] .
Interactions between AAV-2 and HSV-1: implications for hybrid vector design Herpes simplex virus type 1 (HSV-1) -based amplicon vectors have a transgene capacity of up to 150 kbp and can efficiently transduce many different cell types in culture and in vivo without causing cytopathic effects. However, these vectors do not support long-term transgene expression. Adeno-associated virus type 2 (AAV-2) has the capacity to integrate its genome into a specific site on human chromosome 19, but AAV-2-derived gene therapy vectors have a transgene capacity of only 4.5 kb. To combine the large transgene capacity of HSV-1 with the potential for site-specific genomic integration and long-term transgene expression of AAV-2, HSV/AAV hybrid vectors have been developed. This review describes the design, applications and limitations of these hybrid vectors. However, as HSV-1 is a full helper virus for AAV-2 replication, the main focus is the analysis of the molecular mechanisms of interaction between the two viruses. The knowledge of these interactions will have direct implications on the design of novel HSV/AAV hybrid vectors.
Keywords n adeno-associated virus type 2 n herpes simplex virus type 1 n HSV/AAV hybrid vector n HSV-1 amplicon vector n rAAV vector Review Glauser & Fraefel Adeno-associated virus type 2 infects the cell via receptor-mediated endocytosis, with heparan sulfate proteoglycan acting as primary receptor for cell attachment [19] and FGF receptor-1 [20] , integrins aVb1 and aVb5 [21] , the 36/67-kDa laminin receptor [22] and HGF receptor [23] acting as co-receptors. Following receptor binding, A AV-2 enters the cell via a dynamin-dependent clathrin-coated pit endocytosis pathway. A AV-2 escapes from the late endosome and delivers the genome into the nucleus [24] [25] [26] [27] [28] [29] . In the nucleus, the AAV-2 genome is either replicated or becomes latent, depending on the presence or absence of a helper virus. In the presence of a helper virus, A AV-2 genome replication follows a single-strand displacement mechanism termed the 'rolling hairpin model' of DNA replication, with the ITRs acting as primers for second-strand synthesis [30] [31] [32] . Interactions between AAV-2 & HSV-1: implications for hybrid vector design Review
In the absence of a helper virus, the ITRs and either Rep78 or Rep68 can mediate the integration of the AAV-2 genome into a specific site, termed AAVS1, on chromosome 19 of human cells [33] [34] [35] [36] . AAVS1 is closely linked to the muscle-specific genes TNNT1 and TNNI3 [37] .
AAV-2-based gene therapy vectors
Many of its biological properties, in particular the low toxicity and immunogenicity, and stability of gene expression, as well as its simplicity make AAV-2 an interesting platform for vector development [38] . The recombinant (r)AAV vector is a bacterial plasmid that contains a transgene flanked by the AAV-2 ITRs (Figure 2A) . Conventionally, the AAV-2 replicative and structural genes (rep and cap) are provided in trans from a separate plasmid. Following cotransfection of the two plasmids into Ad-or HSV-1-infected cells, the ITR-flanked transgene cassette is replicated and single-stranded replication products are packaged into AAV-2 capsids. Infectious rAAV particles are separated from helper virus particles by density gradient centrifugation. There are many variations to this general packaging strategy with respect to cellular delivery of the three components, the rAAV plasmid vector, rep/cap and helper virus functions [39] [40] [41] [42] [43] [44] . Other recent developments in rAAV vector production include the use of: helper virus-free packaging systems [45] , affinity chromatography for vector purification [19, 46] and the combination of AAV-2 genomes with capsids of other AAV serotypes [47] [48] [49] . Other AAV vector technologies have been developed to increase the transgene capacity [50] or enhance transgene expression [51] .
Recombinant AAV vectors have been used for the delivery of therapeutic genes into many different cell types and tissues. Studies in animal models of various diseases, including Parkinson's disease, diabetes and hemophilia B, as well as in human clinical trials, have been most promising. Some of the target diseases of human clinical gene-therapy trials performed previously using rAAV vectors include: cystic fibrosis [52] [53] [54] , hemophilia [55] , Parkinson's disease [56, 57] and Leber's congenital amaurosis [58] [59] [60] [61] [62] [63] .
Adeno-associated virus-based vectors also have limitations. The small packaging capa city does not allow the insertion of large regulatory sequences, genomic transgene sequences or even some cDNAs. Furthermore, rAAV vector genomes can persist for long periods and support longterm gene expression, but this is not due to sitespecific integration, as rep is in general removed from the ITR cassette to make room for transgene sequences. Adverse effects have also been observed in some of the clinical gene-therapy trials, such as in a clinical trial for hemophilia B; unexpected liver toxicity was observed and was due to a cytotoxic T-lymphocyte response to rAAV-transduced hepatocytes [55] .
Herpes simplex virus type 1
Herpes simplex virus type 1 is a member of the family Herpesviridae and an important human pathogen. The HSV-1 virion has a diameter Figure 1B) . HSV-1 infection starts with the attachment of virion glycoproteins C and B to glycosaminoglycans, preferentially heparan sulfate, on the cellular surface of skin or mucosa [64] [65] [66] [67] [68] . Glycoproteins B, D and the gH-gL complex mediate fusion of the virion envelope with the cell membrane [69] [70] [71] . At least three to four specific cell surface receptors that interact with gD have been identified and designated herpes virus entry mediators [72] [73] [74] [75] [76] . After entry into the cytoplasm, the capsid and tegument proteins are transported along microtubules to the nuclear pores [77] where the DNA is released into the nucleoplasm [78, 79] .
Herpes simplex virus type 1 encodes more than 80 genes. The first genes to be expressed upon infection are the immediate-early (IE) genes, which encode several transactivator proteins, such as ICP0 and ICP4; these initiate transcription of the early genes and some late genes. Early gene products comprise the viral DNA replication factors that initiate viral DNA synthesis. Replication of the viral DNA then stimulates expression of the late genes, which encode structural virion proteins. HSV-1 DNA replication occurs in nuclear domains termed replication compartments (RCs) [80, 81] . Replication starts at the ori and produces large, branched concatemers of head-to-tail linked genomes [82, 83] . Concatemers are cleaved into unit-length genomes at the cleavage/packaging signals (pac) after filling preformed capsids [84] [85] [86] . Different models of HSV-1 maturation, envelopment and egress have been proposed. One model suggests that the virus acquires some tegument proteins and a primary envelope when budding through the inner nuclear membrane. The enveloped virions fuse with the outer nuclear envelope, thereby releasing free nucleocapsids at the cytoplasm that will be re-enveloped in a golgi-related compartment. Re-enveloped virion particles are then secreted by a vesicular route [87] . Another model proposes two distinct pathways. The first pathway involves envelopment at the inner nuclear membrane followed by intraluminal transport to golgi cisternae, where transport vacuoles are formed. Alternatively, capsids leave the nucleus via impaired nuclear pores and are enveloped at the cytoplasmic membranes of the rough endoplasmic reticulum [88, 89] .
The life cycle of HSV-1 is characterized by productive replication in epithelial cells of the mucosa and life-long latent infection in sensory neurons; from there the virus can sporadically reactivate and enter a new lytic replication cycle [90] .
HSV-1-based gene therapy vectors
Two fundamentally different HSV-1-based vector systems, recombinant and amplicon, have been developed to exploit the numerous biological properties that make this virus such an efficient gene-delivery vehicle. Recombinant HSV-1 vectors are created by replacing one or several virus genes with transgene sequences. Depending on the viral genes that are replaced, rHSV-1 vectors can be replication-competent, replication-defective or replication-conditional. Replication-conditional, oncolytic rHSV-1 vectors, rHSV1716 and rHSV-G207, have been assessed in human patients with high-grade gliomas in Phase I clinical trials [91, 92] .
Amplicon vectors are bacterial plasmids that contain a transgene cassette and only two HSV-1 cis elements, an ori and a pac signal, but no viral genes ( Figure 2B ). These two HSV-1 elements are sufficient to support replication of the vector DNA and packaging of the concatemeric replication products into virions in the presence of HSV-1 helper functions. Helper functions can be provided by replication-conditional HSV-1 helper viruses [93] or replication-competent/conditional, packaging-defective HSV-1 genomes cloned as sets of cosmids [94] or bacterial artificial chromosomes [95] [96] [97] . Epstein and co-workers developed a novel strategy for producing large amounts of vector stocks with very low helper virus contamination [98, 99] . This system uses a recombinant HSV-1 helper virus, which contains a pac signal flanked by loxP sites. This recombinant helper virus is replication-and packagingcompetent in normal cells, but when amplicon packaging is performed in cre-recombinaseexpressing cells, the pac signals are efficiently deleted from the helper virus genomes, thereby preventing their packaging into virus particles.
Amplicon vectors conserve most of the properties of the parental virus, including a broad host range, the capability to transduce both dividing and nondividing cells, and a large transgene capacity (up to 150 kbp). This large transgene capacity allows the incorporation of genomic sequences as well as cDNA, large transcriptional regulatory sequences for cell type-specific Since HSV/AAV hybrid vectors can be packaged into HSV-1 virions, they conserve the properties of the HSV-1 amplicon, including high efficiency of gene transfer, large transgene capacity and availability of a helper virus-free packaging system. However, after delivery into the host cell nucleus, the vector has the potential to act like AAV-2, with rep-mediated site-specific integration of the ITR-flanked transgene cassette into the AAVS1 element of human chromosome 19.
Following infection of cultured human glioma cells, HSV/AAV hybrid vectors support transgene expression significantly longer than standard amplicons [102] . Moreover, Heister and colleagues demonstrated that these vectors can indeed mediate site-specific integration at AAVS1 [1] . The junctions between AAVS1 and the hybrid amplicon vectordelivered AAV-2 ITR cassette were similar to those that had been identified in cells infected with wildtype AAV-2 [33] [34] [35] [104] [105] [106] [107] , baculo virus/AAV hybrid vectors [108] or Ad/AAV hybrid vectors [109, 110] . Similar results were obtained by Wang and colleagues who have used human glioma cells (gli36) and primary myoblasts [2] .
In summary, inserting AAV-2 rep and ITRs into the HSV-1 amplicon vector considerably improved the frequency of stable transgene expression in various proliferating human cell types. However, two hurdles to using HSV/AAV hybrid vectors include the low packaging efficiency and low titers due to rep expression, which inhibits HSV-1 DNA replication [1, 2] . A detailed knowledge of the interactions between HSV-1 and AAV-2 may allow us to overcome this hurdle and support the design of novel HSV/AAV-based hybrid vectors that can mediate highly efficient and precise site-specific integration of therapeutic transgenes into the human genome without compromising the vector titers.
Interactions between AAV-2, HSV-1 & the host cell HSV-1 helper functions for AAV-2 replication Replication and packaging of HSV/A AV hybrid amplicon vectors depends on the presence of HSV-1 helper factors, which, however, not only interact with the HSV-1 elements on the hybrid vectors, but, since HSV-1 is a helper virus for AAV-2, also interact with the AAV-2 elements present. A profound understanding of the mechanisms by which HSV-1 helper factors support AAV replication is therefore crucial for the rational design of improved HSV/AAV vectors. The mole cular mechanisms by which helper factors induce AAV-2 replication have been most thoroughly studied for the helper viruses Ad and HSV-1, while the helper effects of other viruses such as papilloma virus [111, 112] and vaccinia virus [113] remain much less-well defined. Comparing the helper activities provided by Ad and HSV-1 allows us to better identify the key features of AAV-2's helper dependence and provides an intriguing illustration of how two different helper strategies ultimately achieve the same end, for example, reactivation and productive replication of AAV-2. The helper effect of Ad on AAV-2 replication is mediated by five early gene products, specifically E1A, E2A, the E1B55K/E4ORF6 complex and the virus-associated (VA)I RNA. Ad E1A function is required for transactivation of the p5 rep promoter [114] , as well as for the induction of S phase [114] [115] [116] [117] [118] . The induction of S phase and the concomitant synthesis of cellular DNA replication factors are likely needed for AAV-2 DNA replication in the presence of Ad helper virus [119] . Consistent with this, cellular DNA polymerases seem to be responsible for AAV-2 replication in the presence of Ad [8, [120] [121] [122] . Ad E2A is a ssDNA-binding protein that supports AAV-2 replication by two distinct mechanisms: first, E2A stimulates transcription from AAV-2 promoters and may be involved in mRNA transport and stability [123, 124] . Second, E2A is preferentially used for AAV-2 DNA replication in place of the cellular ssDNA-binding protein, replication protein A (RPA) [125] . The Ad E1B55K/E4ORF6 complex enhances A AV-2 replication and rAAV-2-mediated transduction by enhancing second-strand synthesis [126, 127] , an effect that has been shown to be mediated by the ability of Review Glauser & Fraefel E1B55K/E4ORF6 to degrade the Mre11/Rad50/ Nbs1 complex [128] . This complex is a conserved multiprotein complex involved in DNA damage sensing, signaling and repair [129] , and its sensing and processing of AAV-2 genome ends has been shown to be inhibitory to AAV-2 second-strand synthesis and DNA replication [128, 130] . Finally, Ad VAI RNA facilitates the initiation of AAV-2 protein synthesis by prevention of the interferoninduced host cell shut-off of translation [131, 132] . In summary, the helper functions provided by Ad help AAV-2 to overcome its deficits in gene expression and DNA replication by the activation of AAV-2 gene expression (via E1A, E2A and VAI RNA), by driving the host cell into S phase and thereby inducing the cellular DNA replication machinery (via E1A), by directly participating in AAV-2 DNA replication (via E2A) and by overcoming cellular barriers to AAV-2 replication imposed by the DNA damage response (via E1B55K/E4ORF6).
Similar to the helper functions provided by Ad, HSV-1 helper functions are also mainly involved in the processes of AAV-2 gene expression and DNA replication (for an overview see Figure 3) . Integrated, latent AAV-2 genomes are transcriptionally silent. In the case of the p5 promoter controlling the expression of the large Rep proteins Rep68 and Rep78, the repression was shown to be due to the Rep68 and Rep78 proteins themselves and to cellular factors including YY1 [11, 114, 133, 134] . An essential first step in productive AAV-2 replication is the expression of the large Rep proteins. Rep68 and Rep78 are not only required for viral DNA replication, but also for efficient transcription from the p19 promoter controlling the expression of the small Rep proteins, Rep40 and Rep52, as well as for transcription from the p40 promoter, directing expression of the capsid proteins VP1, VP2 and VP3 [12] . Activation of the p5 promoter can therefore be considered the initiating event for productive AAV-2 replication. In analogy to Ad E1A, the HSV-1 IE gene product ICP0 was shown to transactivate transcription from the p5 promoter, resulting in Rep68 and Rep78 synthesis [135] . However, ICP0 also induced the synthesis of Rep40 and Rep52, which is controlled by the p19 promoter. It is currently not known if the induction of Rep40 and Rep52 synthesis by ICP0 involves a direct activation of the p19 promoter by ICP0 or if the effect is indirectly mediated by the Rep68 and Rep78 proteins [12, 135] . Although ICP0 is considered a promiscuous transactivator of gene expression [136] , the effect on rep expression seems specific, in that ICP0 does not activate cap expression [135] . The induction of rep expression is strictly dependent on the E3 ubiquitin ligase activity of the ICP0 RING-finger domain and on proteasome activity, Interactions between AAV-2 & HSV-1: implications for hybrid vector design Review suggesting that derepression of the p5 promoter involves the ICP0-induced degradation of one or several cellular factors [135, 137] . Activation of the p5 promoter by ICP0 also involves the interaction of ICP0 with the deubiquitylating enzyme USP7/HAUSP, which, however, is not essential [135, 137] . It was recently shown that transactivation of rep expression by ICP0 can be further enhanced by the presence of two other HSV-1 IE proteins, ICP4 and ICP22 [138] . On their own, ICP4 stimulates rep expression only marginally, while ICP22 has no effect [138] . ICP4 is a transactivator protein essential for HSV-1 replication and is required for expression of several early and late genes [139] . ICP4 may enhance the effect of ICP0 by physically interacting with the latter or by direct binding to degenerate binding sites in the p5 promoter [140, 141] . ICP22 stimulates the expression of some HSV-1 late genes and is involved in the alteration of cell-cycle regulatory proteins and in the modification of cellular RNA polymerase II [142, 143] . The molecular mechanism by which ICP22 contributes to transactivation of rep expression remains, however, unknown [138] . rep expression from AAV-2 genomes delivered into the cell by infection or transfection is less tightly repressed than that of AAV-2 genomes integrated into the host cell genome. Consequently, low-level rep expression can be observed even in the absence of helper virus, which is, however, significantly enhanced by the presence of ICP0, ICP4 and ICP22 [138] . AAV-2 replication upon infection or transfection is therefore much less dependent on rep transactivation by ICP0, ICP4 and ICP22 than reactivation of latent virus [138, 144] .
Once Rep68 and Rep78 proteins are produced in sufficient amounts, they are thought to transactivate expression from the p19 and p40 promoters, leading to synthesis of Rep40/Rep52 and the capsid proteins, respectively [12] . Rep40 and Rep52, in turn, prevent the autorepressive activity of Rep68 and Rep78 on the p5 promoter, resulting in high levels of Rep68 and Rep78 during lytic replication [12] . Simultaneously, the large Rep proteins initiate AAV-2 DNA replication by binding to the RBSs in the ITR and p5 oris followed by nicking at the TRSs, the latter creating primers for repair synthesis of the ITRs [145] . It is at this stage of its replication cycle that AAV-2 again depends on help from HSV-1, specifically the presence of the ssDNA-binding protein ICP8 (encoded by UL29), the helicase-primase complex (encoded by UL5, UL8 and UL52) and the DNA polymerase holoenzyme (encoded by UL30 and UL42) [138] . It is thought that during AAV-2-HSV-1 coinfection, the AAV-2 DNA is replicated by the HSV-1 replication machinery assembling on the AAV-2 oris [120] . In analogy to the HSV-1 ori-binding protein UL9 [146] , Rep probably triggers the assembly of the replication machinery by binding to the RBSs within the AAV-2 oris. In the next step, Rep68 and Rep78 are thought to recruit ICP8 through a direct protein-protein interaction, which in turn stimulates Rep DNA-binding and nicking activity [147, 148] . The Rep68/78-ICP8 complex is then thought to recruit the helicase-primase complex, as well as the DNA polymerase holoenzyme. Among the HSV-1 replication factors involved in AAV-2 replication, ICP8 can certainly be considered a key helper factor, since its presence is crucial to processive AAV-2 DNA replication. The function of ICP8 presumably lies in its ability to stabilize ssDNA and to hold the replication fork in an extended conformation [149] , as well as in its ability to act as a scaffolding protein for the recruitment of the helicase-primase complex and the polymerase holoenzyme [90, 147] . Consistent with a key role in the helper activity, the mere addition of purified ICP8 to extracts from uninfected HeLa cells is sufficient to support in vitro AAV-2 DNA replication [148] . The function of the helicase-primase complex in AAV-2 replication appears to be somewhat more complicated. Review Glauser & Fraefel On one hand, the helicase-primase complex is not required for in vitro AAV-2 DNA replication [8, 148] . On the other hand, all three components, UL5, UL8 and UL52, are strictly required for in vivo AAV-2 replication (i.e., in infected or transfected cells) [138, 144] . More specifically, the role of the helicase-primase complex for in vivo AAV-2 replication can be divided into its role as a scaffolding protein and its role as an enzyme. For its role as a scaffolding protein in the assembly of replication complexes, neither the helicase activity of UL5, nor the primase activity of UL52 are required [150] . By contrast, the UL5 helicase, but not the UL52 primase activity, is required for efficient in vivo AAV-2 DNA replication [150] . While the dispensability of the UL52 primase activity is consistent with the fact that AAV-2 DNA synthesis proceeds exclusively via leadingstrand synthesis [145] , the requirement for the 5´-3´ helicase activity of UL5 in addition to the 3´-5´ helicase activity of Rep is less obvious. The role of the HSV-1 DNA polymerase in AAV-2 replication has remained somewhat controversial. On one hand, the findings that the AAV-2 replication complexes extracted from AAV-2-HSV-1-coinfected cells mainly contain the HSV-1 DNA polymerase [120] and that the HSV-1 DNA polymerase holoenzyme is capable of replicating AAV-2 DNA in a reconstituted in vitro system [8] support the notion that AAV-2 DNA is replicated by the HSV-1 DNA polymerase. On the other hand, the requirement for the HSV-1 polymerase is not absolute, in that AAV-2 DNA replication can also be observed in the absence of the HSV-1 DNA polymerase, although at reduced levels [138, 144] . These observations presumably reflect the fact that the extent to which AAV-2 DNA synthesis is mediated by the HSV-1 DNA polymerase and cellular DNA polymerases depends on their respective abundance. In the case of the Ad helper virus, E1A directs the host cell into S phase, inducing cellular polymerase activity, while HSV-1 helper virus provides polymerase activity via the UL30 and UL42 gene products. In cells transfected with only the minimal HSV-1 helper factors UL5, UL8, UL52 and ICP8, or in cells infected with polymerase-deficient HSV-1, AAV-2 DNA is replicated by cellular polymerases, but presumably only in the subset of cells that are in S phase. In summary, the helper functions provided by both Ad and HSV-1 helper viruses help AAV-2 to overcome two major barriers to productive replication: rep expression and DNA replication. This is achieved by transactivation of the p5 rep promoter and by facilitation of AAV-2 DNA replication by direct participation of helper factors in AAV-2 DNA replication and, in the case of Ad, additionally directing the host cell into S phase. An overview of the HSV-1 helper functions for AAV-2 replication is provided in TABle 1.
Interactions at the level of viral replication compartments
The presence of HSV-1 helper factors during HSV/AAV hybrid vector replication and packaging not only leads to hybrid vector replication from the HSV-1 ori, but also to AAV-2 rep expression and consequently to rescue and replication of the ITR-flanked transgene cassette [1] . Studying the interaction of replicating HSV-1 and AAV-2 DNA may therefore provide useful insight into the molecular mechanisms underlying the lower replication efficiency of HSV/AAV hybrid vectors compared with standard HSV-1 amplicon vectors. Analogous to the situation with other DNA viruses, AAV-2 DNA replication occurs in nuclear RCs, in which AAV-2 DNA co localizes with Rep proteins and components of the DNA Interactions between AAV-2 & HSV-1: implications for hybrid vector design Review replication machinery [28, 147, 148, 151] . AAV-2 DNA replication initiates at small nuclear foci, so-called pre-replicative sites, which grow in size and appear to coalesce into large globular structures, eventually filling out most of the nucleus and displacing cellular chromatin to the nuclear periphery [14, 28, 151] . In the case of Ad as the helper virus, AAV-2 DNA initially colocalizes with Ad DNA, suggesting that AAV-2 is recruited into Ad RCs [28] . However, while the AAV-2 RCs develop into large globular structures, the maturation of the Ad RCs is inhibited by the presence of AAV-2 [28] .
In contrast to the situation with Ad, AAV-2 and HSV-1 helper viruses were shown to replicate in spatially separate RCs [152] . The RCs of AAV-2 and HSV-1 could not only be distinguished by direct visualization of the viral DNA, but also by the set of viral and cellular proteins that they recruited. To directly visualize replicating AAV-2 and HSV-1 DNA in live cells, rAAV-2 plasmids and HSV-1 amplicon plasmids containing multiple lac operator and tetracycline operator repeats, respectively, were visualized by binding of lac repressor and tetra cycline repressor fused to autofluorescent proteins. Such visualization systems allow time-lapse analysis of viral RCs and, if combined with indirect immunofluorescence or transfection of fluorescently tagged replication factors, analysis of the set of proteins associated with the viral RCs [14, 151, 152] . Specifically, it was shown that the large Rep proteins are recruited into AAV-2, but not into HSV-1 RCs [152] , an observation that can be readily explained by the presence of stronger RBSs in the AAV-2 genome than in the HSV-1 genome [153] . By simultaneous visualization of AAV-2 DNA replication from the alternative oris within the ITRs and the p5 promoter, it was previously shown that the degree of colocalization of Rep68 and Rep78 proteins with replicating DNA substrates correlates with their affinity for the RBSs within the respective oris [14] . In contrast to Rep, the essential helper factor ICP8 was demonstrated to be equally recruited into both AAV-2 and HSV-1 RCs, although with differential staining patterns [152] . Specifically, ICP8 adopted a punctate staining pattern within HSV-1 RCs, consistent with binding to the ssDNA present at the replication forks, but not to the dsHSV-1 replication products [152] . By contrast, ICP8 adopted a more diffuse pattern within AAV-2 RCs, presumably reflecting binding of ICP8 to AAV-2 replication forks, as well as to ssDNA on AAV-2 replication products [152] . Similar to the situation for ICP8, the HSV-1 DNA polymerase catalytic subunit UL30 was shown to be recruited to both HSV-1 and AAV-2
RCs, a finding that is consistent with the HSV-1 DNA polymerase being involved in AAV-2 DNA replication [Glauser DL et al [81, 154] . However, in the absence of replicating HSV-1 DNA (i.e., in the presence of transfected HSV-1 helper factors), ICP4 was recruited into AAV-2 RCs, suggesting that ICP4 may also show weak binding to AAV-2 DNA [138] . Finally, RPA was shown to be hyperphosphorylated and recruited into AAV-2 RCs [148] , while hyperphosphorylation of RPA was not induced during HSV-1 replication and the low levels of endogenous hyper phosphorylated RPA were spatially excluded from HSV-1 RCs by sequestration into virus-induced chaperoneenriched domains [155, 156] . RPA is a heterotrimeric ssDNA-binding protein consisting of 70-, 32-and 14-kDa subunits involved in diverse processes such as DNA replication, DNA repair, recombination and DNA damage signaling [157] . It is thought that RPA participates in AAV-2 DNA replication and that it is recruited into AAV-2 replication complexes by a direct interaction with Rep68 and Rep78 [125, 148] . The finding that AAV-2 and HSV-1 replicate in spatially independent RCs is consistent with the hypothesis that HSV-1 and AAV-2 RCs are clonal (i.e., derived from individual parental virus genomes) and that both the viral DNA and the associated proteins cannot freely move between individual RCs [14, 81, 158] . But what are the implications of these observations for the reciprocal interactions between AAV-2 and HSV-1? The finding that the sites of AAV-2 and HSV-1 DNA replication are spatially separated implies that the spatial separation also applies to the helper factors associated with AAV-2 and HSV-1 replication complexes. Since most of the HSV-1 helper factors involved in AAV-2 replication are also essential for HSV-1 replication, it is conceivable that their recruitment away from HSV-1 RCs into AAV-2 RCs might result in an inhibition of HSV-1 replication. Indeed, the maturation of HSV-1 RCs is inhibited in the presence of replicating AAV-2 DNA [152] . The inhibitory effect of AAV-2 on HSV-1 does, however, not strictly depend on the presence of replicating AAV-2 DNA. Instead, the mere presence of the large Rep proteins is sufficient for considerable inhibition of HSV-1 replication, suggesting that they have an intrinsic ability to interfere with HSV-1 DNA replication [152] . The latter finding does not, however, exclude an additional role of competition for future science group Review Glauser & Fraefel replication factors in the inhibition of HSV-1 replication. Indeed, support for the hypothesis that AAV-2 and HSV-1 compete for replication factors stems from experiments where HSV-1 helper factors were provided by infection with a recombinant virus lacking the HSV-1 oribinding protein UL9 or by transfection of the HSV-1 helper factors with or without UL9 [144] . Since UL9 is essential for HSV-1 replication, but not for AAV-2 replication, its absence specifically prevents HSV-1 replication while allowing AAV-2 replication. Both in the situation of HSV-1 infection and transfection of HSV-1 helper factors, the replication of AAV-2 proceeds more efficiently in the absence of UL9, suggesting that the absence of HSV-1 DNA replication increases the availability of helper factors for AAV-2 DNA replication [144] . It is therefore plausible that the presence of replicating AAV-2 DNA similarly limits the availability of essential replication factors for HSV-1 replication. In summary, DNA replication of AAV-2 and that of its helper virus HSV-1 occurs in spatially separate nuclear RCs that can be distinguished by the direct visualization of viral DNA, as well as by the set of viral and cellular proteins associated with them. It is thought that the spatial separation of AAV-2 and HSV-1 DNA replication leads to some competition for replication factors essential for both viruses such as the helicase-primase complex and ICP8, and that such competition may be involved in the inhibited replication of HSV-1 in the presence of AAV-2. However, the presence of Rep68 and Rep78 without replicating AAV-2 DNA is sufficient for significant inhibition of HSV-1 RC maturation, suggesting that inhibition of HSV-1 replication by AAV-2 also involves a direct inhibitory effect of Rep proteins.
Effects of AAV-2 Rep on HSV-1 replication & the host cell
The abovementioned observation of inhibited HSV-1 RC maturation in the presence of replicating AAV-2 or AAV-2 Rep68 and Rep78 proteins [152] is corroborated by several other findings. Specifically, coinfection with AAV-2, AAV-3 or AAV-5 was demonstrated to inhibit the accumulation of HSV-1 DNA in a dose-dependent manner [152, 159] . In addition, it was shown that the expression of the AAV-2 Rep proteins was sufficient for inhibition of ori of the short fragment (ori S )-dependent HSV-1 DNA replication in transfected cells [160] . Consistent with these findings, the presence of the rep gene on HSV/AAV hybrid amplicon vectors was shown to result in significantly reduced titers of vector stocks [1] . Besides inhibiting HSV-1 replication, AAV-2 Rep has also been shown to have inhibitory effects on its other helper virus, Ad [28] , as well as on the host cell [161, 162] . The inhibitory effect of Rep on Ad has been suggested to occur primarily at the level of DNA replication [163] , although several effects on Ad gene expression have also been demonstrated [164] [165] [166] [167] . Although it is thought that the inhibitory effect of AAV-2 on its helper viruses contributes to the replication fitness of AAV-2 in coinfected cells, it can also lead to autoinhibition. Specifically, at very high AAV-2 doses or high Rep expression levels, the inhibitory effect on Ad is so pronounced that it actually results in reduced levels of AAV-2 replication due to insufficient synthesis of Ad helper factors [168, 169] . The inhibitory effects of Rep on the host cell include the induction of DNA damage, cell-cycle arrest and apoptosis [170] [171] [172] , implying that the effects of Rep on HSV-1 and Ad replication may either be direct or else a consequence of the effects of Rep on the host cell. The molecular mechanisms underlying the inhibitory effect of Rep on HSV-1 were addressed in a recent study [153] . Analysis of a panel of Rep proteins lacking defined domains and activities revealed that the inhibitory effect on HSV-1 replication required the Rep DNA-binding and ATPase/helicase activities. Specifically, while Rep78 strongly inhibited HSV-1 replication, the inhibitory activity was lost for Rep52 lacking the N-terminal DNA-binding and endonuclease domains, as well as for a mutant Rep78 protein, Rep78(K340H), lacking ATPase/helicase activity due to a mutated NTP-binding site [153] . By contrast, Rep68, which lacks the C-terminal domain of Rep78, as well as a mutant Rep78 protein that has no endonuclease activity [173, 174] , inhibited HSV-1 replication just as strongly as the full-length Rep78 protein [153] . In addition, it was found that the DNA-binding activity and the ATPase/helicase activity need to be present on the same Rep molecule, since trans-complementation of Rep DNA-binding and ATPase/helicase activities did not restore the inhibitory effect [153] . Together, these findings suggest that Rep DNA-binding and ATPase/helicase activities, but not endonuclease activity, are required for the inhibitory effect on HSV-1 replication, and that both activities need to be present on the same Rep molecule. Rep78 had a moderate inhibitory effect on HSV-1 IE and early gene expression, but a strong inhibitory effect on HSV-1 DNA replication and late gene expression. Although Rep78 moderately reduced HSV-1 early gene expression, this effect was shown not to account future science group
Interactions between AAV-2 & HSV-1: implications for hybrid vector design Review for the reduced HSV-1 DNA replication, suggesting that Rep78 was directly interfering with HSV-1 DNA replication [153] . Intriguingly, the Rep activities required for inhibition of HSV-1 replication precisely coincided with those responsible for induction of DNA damage and apoptosis [153, 172] . However, preventing the execution of apoptosis with caspase inhibitors did not prevent the inhibition of HSV-1 replication, nor did Rep induce apoptosis in HSV-1-infected cells, together suggesting that the execution of apoptosis is not involved in the inhibitory effect on HSV-1 [153] . The DNA damage response elicited by Rep68 and Rep78 is characterized by hyperphosphorylation of ATM, RPA32, Chk2 and H2AX, with the activation of H2AX depending on ATM function [153, 170] . By contrast, HSV-1 infection induces activation of ATM, Chk2 and H2AX, but not of RPA [155, 156, 175, 176] . The low levels of endogenous hyperphosphorylated RPA are even sequestered away from HSV-1 RCs into virusinduced chaperone-enriched domains [155, 156] , suggesting that they may be inhibitory to HSV-1 replication. It was therefore hypothesized that activation of RPA by Rep might be responsible for inhibition of HSV-1 replication. However, hyperphosphorylation of RPA induced by other means, such as camptothecin or infection with UV-inactivated AAV-2 [177, 178] , did not reduce HSV-1 replication, suggesting that the activation of RPA per se is not involved in the inhibitory effect of Rep on HSV-1 [153] . It therefore appears that the ability of Rep to induce DNA damage, rather than the cellular response to it, is responsible for the inhibitory effect on HSV-1. Although the currently available data suggest that Repinduced DNA damage, cell-cycle arrest, apoptosis and inhibition of HSV-1 are mediated by the binding of Rep to degenerate RBSs within the cellular and HSV-1 DNA followed by unwinding via the ATPase/helicase activity [153, 170, 172] , the exact mechanisms by which Rep induces the DNA damage remain unsolved. Since Rep endonuclease activity is not required for the induction of DNA damage [153] , it remains somewhat unclear how Rep DNA binding and unwinding results in an activation of ATM, which is considered to be a marker for double-strand breaks (DSBs) [179] . However, a recent report on the Rep homolog of parvovirus H-1, NS1, showed that NS1-induced DNA damage, cell-cycle arrest and apoptosis are mediated by the accumulation of reactive oxygen species (ROS) known to result in DSBs [180] . The NS1 activities involved in the induction of ROS remain unknown [180] , and it is therefore difficult to speculate about a possible mechanism. Nonetheless, it is possible that NS1 stimulates the expression of genes involved in ROS production or in the regulation of ROS homeostasis and that this is responsible for the observed DNA damage and the resulting cellcycle arrest and apoptosis [180] . It is tempting to speculate that AAV-2 Rep induces DSBs through a similar mechanism and that this accounts for the observed DNA damage response, cell-cycle arrest, apoptosis and inhibition of HSV-1 replication. However, further clarification of this issue awaits an experimental assessment of the role of ROS in AAV-2 Rep-induced DNA damage.
Conclusion & future perspective On the analysis of AAV-HSV interactions
The fact that AAV-2 can only productively replicate in cells that are coinfected with a helper virus inevitably leads to a complex network of interactions between AAV-2, the helper virus and the host cell. A successful replication strategy for AAV-2 must allow efficient expression of the helper factors while ensuring that the replication of the helper virus does not proceed unchecked in order to limit competition for helper factors and cellular resources. Indeed, AAV-2 is thought to allow the efficient expression of HSV-1 IE genes, including the helper factors ICP0, ICP4 and ICP22, which are important to trans activate AAV-2 rep gene expression [135, 138, 152] . The HSV-1 IE gene products simultaneously transactivate HSV-1 early gene expression, resulting in the synthesis of a second set of helper factors, the ssDNA-binding protein ICP8, the helicase-primase complex and the DNA polymerase holoenzyme [138, 144] . These helper factors are then thought to be recruited to the AAV-2 oris by a direct interaction of the large Rep proteins with ICP8 and to provide the replication machinery for AAV-2 DNA replication, the latter proceeding in RCs spatially separated from those of the helper virus [120, 147, 148, 152] . The large Rep proteins also seem to have an intrinsic ability to inhibit the replication of cellular and HSV-1 DNA, which is dependent on their DNA-binding and ATPase/helicase activities [152, 153, 160, 170] . By interfering with HSV-1 DNA replication, AAV-2 is thought to limit the competition of HSV-1 DNA for the HSV-1 replication machinery. Although the currently available data provide important clues in support of such a model, many aspects still remain elusive. Of particular interest are the molecular mechanisms by which Rep seems to selectively interfere with the replication of cellular and HSV-1 DNA while allowing efficient AAV-2 DNA replication. It is plausible that such specificity is simply based on the fact that, within the Review Glauser & Fraefel AAV-2 genome, the Rep proteins are specifically targeted to the ITRs and p5 oris, where they fulfill an essential function for the repair synthesis of the ITRs [145] . However, at high Rep concentrations, Rep binding to degenerate cellular and HSV-1 RBSs occurs at random locations, where it potentially interferes with DNA replication and transcription. A crucial point in understanding the effects of Rep on HSV-1 and the cell appears to be the understanding of the mechanism by which Rep induces DNA damage. In light of the recent finding that this does not require Rep endonuclease activity [153] , this mechanism seems to be more complicated than was previously thought [170] . However, very recent findings about the Rep homolog NS1 of parvovirus H-1 demonstrate that NS1-induced DNA damage, cell-cycle arrest and apoptosis are mediated by the induction of ROS, suggesting that NS1 may induce expression of genes involved in ROS production or in regulation of ROS homeostasis [180] . Whether a similar mechanism is involved in AAV-2 Rep-induced DNA damage, cell-cycle arrest, apoptosis and inhibition of HSV-1 remains to be determined in future studies.
On HSV/AAV hybrid vector design
The ability of Rep to interfere with HSV-1 DNA replication has so far hampered the efficient production of HSV/AAV hybrid amplicon vectors [181] . To circumvent this problem, several approaches are possible, some of which have been addressed experimentally:
n The design of HSV/AAV hybrid amplicon vectors that restrict rep expression to the time frame from transduction to site-specific integration: specifically, the HSV/AAV hybrid vectors were designed in such a way that little or no rep was expressed during vector replication and packaging. However, rep was expressed in transduced cells expressing Crerecombinase. Following site-specific integration, rep was suppressed again in order to increase the stability of the integrated transgene [182] . The major drawback of this approach, however, is its dependence on Crerecombinase-expressing target cells, making it unfeasible for in vivo treatments; n The design of HSV/AAV amplicon vectors that replicate from an AAV-2 instead of an HSV-1 ori: since Rep selectively inhibits DNA replication from HSV-1 oris while allowing efficient replication from AAV-2 oris [153] , an HSV/AAV amplicon vector in which the HSV-1 ori S is replaced by an AAV-2 ori (p5 or ITR) has the potential to replicate to high titers in the presence of Rep proteins. Indeed, a HSV/AAV hybrid amplicon vector containing the AAV-2 p5 ori and the HSV-1 pac signal is replicated and packaged into HSV-1 virions in the presence of HSV-1 helper factors [14] . However, the efficiencies of vector production and site-specific integration compared with conventional HSV/AAV hybrid amplicon vectors remain to be determined;
n The incorporation of Rep proteins into the HSV-1 particle by fusion to the HSV-1 VP16 tegument protein: in this approach, the fulllength AAV-2 rep gene is fused to the C-terminus of full-length HSV-1 UL48 (encoding VP16) in the packaging-deficient helper DNA (fHSVDpacD27Dkn). Notably, this approach is different from previously described Interactions between AAV-2 & HSV-1: implications for hybrid vector design Review
Rep-VP16 chimeras, in which the DNA-binding domain of Rep was fused to the VP16 activation domain in a study concerned with in vivo analysis of Rep DNA binding [184] . During the vector replication/packaging process, the VP16-Rep fusion protein is synthesized and incorporated into the vector particle, while the corresponding fusion gene remains unpackaged due to the packaging-deficiency of the helper DNA. As the VP16-Rep fusion proteins would be synthesized late in HSV-1 infection (VP16 is expressed with leaky late [g1] expression kinetics), this would lead to only minimal inhibition of vector DNA replication. Upon transduction of the target cell, the VP16-Rep fusion is expected to be released from the virion and translocated to the nucleus, where it potentially mediates the site-specific integration of the HSV/AAV hybrid vector DNA. We have assessed the feasibility of this approach and have successfully created HSV-1 helper genomes bearing the corresponding fusion protein. Although such helper DNA supports the replication and packaging of HSV/AAV hybrid amplicon vectors, the efficiency of site-specific vector integration remains to be determined In summary, while the ability of the large AAV-2 Rep proteins to inhibit HSV-1 DNA replication confers to A AV-2 a competitive advantage over HSV-1 during coinfection, it poses a significant problem for HSV/AAV hybrid vector design in that it hampers efficient hybrid vector production. Several strategies have been addressed to circumvent this problem, including controlling the expression or activity of Rep during vector production, the incorporation of mutant rep genes with reduced inhibitory effects on HSV-1, the replication of hybrid vector genomes from AAV-2 instead of HSV-1 replication origins and, finally, the incorporation of the Rep protein into the hybrid vector particle by fusion to VP16 tegument protein. Although research into most of these approaches is still in its early phases, several feasible strategies seem to have emerged. Whether one of them will ultimately lead to the development of optimal HSV/AAV hybrid amplicon vectors replicating to high titers and mediating efficient and stable site-specific integration with concomitant long-term in vivo transgene expression remains to be shown; however, it certainly seems that this aim will become achievable in the near future.
Executive summary
Herpes simplex virus type 1 n Herpes simplex virus type 1 (HSV-1) is a member of the Herpesviridae family. Its genome is a dsDNA of 150 kbp that encodes more than 85 proteins.
n HSV-1 has been used for the construction of two fundamentally different types of gene therapy vectors. Recombinant HSV-1 vectors are created by replacing one or several virus genes with transgene sequences. HSV-1 amplicon vectors are bacterial plasmids that contain two cis elements from the HSV-1 genome, an origin of DNA replication and a DNA packaging/cleavage signal; they have a transgene capacity of up to 150 kbp. Amplicon vectors depend on helper functions for replication and packaging.
Adeno-associated virus type 2
n Adeno-associated virus type 2 (AAV-2) is a member of the Parvoviridae family. Its genome is a ssDNA of 4.7 kb that encodes eight proteins. AAV-2 can establish latent infections by genomic integration, preferentially at AAVS1 on human chromosome 19.
n AAV-2-based gene therapy vectors are created by replacing the viral rep and cap genes with transgene sequences. AAV-2 vectors depend on helper functions for replication and packaging.
HSV/AAV hybrid vectors
n HSV/AAV hybrid vectors have been constructed to combine the large transgene capacity of HSV-1 with the potential for site-specific genomic integration and long-term transgene expression of AAV-2.
Replication compartment
n DNA viruses replicate in specialized subnuclear structures, termed replication compartments, in which virus DNA colocalizes with viral and cellular components of the DNA replication machinery. 
